[6-K] Haleon plc Current Report (Foreign Issuer)

Rhea-AI Filing Summary

Haleon plc reported PDMR share transactions under its Share Reward Plan. On 11 November 2025, Adrian Morris (General Counsel) and Tamara Rogers (Chief Marketing Officer) each acquired 33 ordinary shares at £3.718992 and received 33 matching shares at £Nil on the London Stock Exchange.

These notifications were made in accordance with the UK Market Abuse Regulation and reflect routine participation in the company’s employee share plan.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2025

Commission File Number: 001-41411

Haleon plc

(Translation of registrant’s name into English)

Building 5, First Floor, The Heights,

Weybridge, Surrey, KT13 0NY

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

EXHIBIT INDEX

Exhibit Number	Description
99.1	12 November 2025 - “Director/PDMR Shareholding”

99.1

​Haleon plc: Director/PDMR Shareholding

​

12 November 2025: Haleon plc (the "Company" or "Haleon") (LSE/NYSE:HLN) today announces notification and public disclosure in accordance with the requirements of The UK Market Abuse Regulation of Transactions by Persons Discharging Managerial Responsibilities ("PDMRs").

On 12 November 2025, the Company received notification of the following transactions as detailed below.

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Adrian Morris
2	Reason for the notification
a)	Position/status	General Counsel - PDMR
b)	Initial notification /Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Haleon plc
b)	LEI	549300PSB3WWEODCUP19
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary Shares of £0.01 each
	Identification code	GB00BMX86B70
	b)	Nature of the transaction	Acquisition of Partnership Shares and award of Matching Shares under the Company's Share Reward Plan
	c)	Price(s) and volume(s)
			Price(s)	Volume(s)
			£3.718992	33
			£Nil	33 (Matching Shares)
d)		Aggregated information
	- Aggregated volume	66
	- Price
	e)	Date of the transaction	11 November 2025
	f)	Place of the transaction	London Stock Exchange (XLON)

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Tamara Rogers
2	Reason for the notification
a)	Position/status	Chief Marketing Officer - PDMR
b)	Initial notification /Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Haleon plc
b)	LEI	549300PSB3WWEODCUP19
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary Shares of £0.01 each
	Identification code	GB00BMX86B70
	b)	Nature of the transaction	Acquisition of Partnership Shares and award of Matching Shares under the Company's Share Reward Plan
	c)	Price(s) and volume(s)
			Price(s)	Volume(s)
			£3.718992	33
			£Nil	33 (Matching Shares)
d)		Aggregated information
	- Aggregated volume	66
	- Price
	e)	Date of the transaction	11 November 2025
	f)	Place of the transaction	London Stock Exchange (XLON)

Amanda Mellor

Company Secretary

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.

For more information, please visit www.haleon.com.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		HALEON PLC (Registrant)
Date: November 12, 2025	By:	/s/ Amanda Mellor
		Name:	Amanda Mellor
		Title:	Company Secretary

FAQ

What did Haleon (HLN) disclose in this Form 6-K?

Haleon disclosed PDMR transactions under its Share Reward Plan, with two executives acquiring 33 shares at £3.718992 and receiving 33 matching shares at £Nil.

Which Haleon executives were involved and in what amounts?

Adrian Morris and Tamara Rogers each acquired 33 ordinary shares and received 33 matching shares.

What was the purchase price for the Haleon shares?

The partnership shares were acquired at £3.718992 per share; matching shares were awarded at £Nil.

When and where were the transactions executed?

The transactions took place on 11 November 2025 on the London Stock Exchange (XLON).

What regulation governs these Haleon disclosures?

They were notified in accordance with the UK Market Abuse Regulation for PDMR transactions.

What type of shares were involved in the Haleon transactions?

Ordinary shares of £0.01 each, ISIN GB00BMX86B70.